Cytokinetics, Incorporated
CYTK
$43.27
-$0.61-1.39%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 3,555.94% | 85.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3,555.94% | 85.94% | |||
| Cost of Revenue | 10.66% | 6.30% | |||
| Gross Profit | 8.85% | -6.05% | |||
| SG&A Expenses | 10.04% | 11.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.41% | 8.31% | |||
| Operating Income | 1.25% | -8.17% | |||
| Income Before Tax | 6.56% | -12.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.56% | -12.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.56% | -12.02% | |||
| EBIT | 1.25% | -8.17% | |||
| EBITDA | 1.25% | -8.32% | |||
| EPS Basic | 6.87% | -3.98% | |||
| Normalized Basic EPS | 6.86% | -3.98% | |||
| EPS Diluted | 6.87% | -3.98% | |||
| Normalized Diluted EPS | 6.86% | -3.98% | |||
| Average Basic Shares Outstanding | 0.33% | 7.73% | |||
| Average Diluted Shares Outstanding | 0.33% | 7.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
